STING1 and neoplasm: As mentioned above, the current study found that cGAS and IRF3 played important roles in the inhibition of tumor growth by paclitaxel, combining an agonist of the cGAS-STING signaling pathway with paclitaxel could significantly improve the efficacy (Zierhut et al., 2019; Du et al., 2021).